16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Nasal polyps
- Focus Therapeutic Use
- Sponsors OptiNose
- 10 Dec 2018 According to an OptiNose media release, first patient has been enrolled in the trial.
- 26 Nov 2018 New trial record
- 19 Nov 2018 Planned End Date changed from 10 Dec 2020 to 31 Dec 2019.